Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment

Journal Article · Mon Nov 01 00:00:00 EDT 2010 · Toxicology and Applied Pharmacology

DOI:https://doi.org/10.1016/j.taap.2010.08.006· OSTI ID:21451192

Taguchi, Kazuaki; Miyasato, Mayumi; Ujihira, Hayato ^[1]; Watanabe, Hiroshi; Kadowaki, Daisuke ^[1]; Sakai, Hiromi; Tsuchida, Eishun ^[2]; Horinouchi, Hirohisa; Kobayashi, Koichi ^[3]; Maruyama, Toru ^[1]; Otagiri, Masaki ^[1]

---

1. Department of Biopharmaceutics, Kumamoto University, 5-1 Oe-honmachi, 862-0973 Kumamoto (Japan)
2. Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, 169-8555 Tokyo (Japan)
3. Department of Surgery, School of Medicine, Keio University, 35 Shinano Shinjyuku, 160-8582 Tokyo (Japan)

The hemoglobin vesicle (HbV) is an artificial oxygen carrier in which a concentrated Hb solution is encapsulated in lipid vesicles. Our previous studies demonstrated that HbV is metabolized by the mononuclear phagocyte system, and the lipid components are excreted from the liver. It is well-known that many hepatically-metabolized and -excreted drugs show altered pharmaceutics under conditions of liver impairment, which results in adverse effects. The aim of this study was to determine whether the administration of HbV causes toxicity in rats with carbon tetrachloride induced liver cirrhosis. Changes in plasma biochemical parameters, histological staining and the pharmacokinetic distribution of HbV were evaluated after an HbV injection of the above model rats at a putative clinical dose (1400 mgHb/kg). Plasma biochemical parameters were not significantly affected, except for a transient elevation of lipase, lipid components and bilirubin, which recovered within 14 days after an HbV infusion. Negligible morphological changes were observed in the kidney, liver, spleen, lung and heart. Hemosiderin, a marker of iron accumulation in organs, was observed in the liver and spleen up to 14 days after HbV treatment, but no evidence of oxidative stress in the plasma and liver were observed. HbV is mainly distributed in the liver and spleen, and the lipid components are excreted into feces within 7 days. In conclusion, even under conditions of hepatic cirrhosis, HbV and its components exhibit the favorable metabolic and excretion profile at the putative clinical dose. These findings provide further support for the safety and effectiveness of HbV in clinical settings.

• OSTI ID: 21451192
• Journal Information: Toxicology and Applied Pharmacology, Vol. 248, Issue 3; Other Information: DOI: 10.1016/j.taap.2010.08.006; PII: S0041-008X(10)00279-6; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0041-008X
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS
60 APPLIED LIFE SCIENCES
BLOOD SERUM
HEMOGLOBIN
HEMOSIDERIN
KIDNEYS
LIVER
LUNGS
MORPHOLOGICAL CHANGES
RATS
SPLEEN
TOXICITY
ANIMALS
BIOLOGICAL MATERIALS
BLOOD
BLOOD PLASMA
BODY
BODY FLUIDS
CARBOXYLIC ACIDS
DIGESTIVE SYSTEM
GLANDS
GLOBINS
HETEROCYCLIC ACIDS
HETEROCYCLIC COMPOUNDS
MAMMALS
MATERIALS
METALLOPROTEINS
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PIGMENTS
PORPHYRINS
PROTEINS
RESPIRATORY SYSTEM
RODENTS
VERTEBRATES